Modulators of lysophosphatidic acid signalling

Bibliography

• FANG X, GAUDETTE D, FURUI T et al: Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. NY Acad. Sci. (2000) 905:188–208.
   PubMed Web of Science ®Google Scholar
• ••Review of the involvement of LPA andLPC in ovarian cancer.
   Google Scholar
• HLA T, LEE MJ, ANCELLIN N, PAIK JH, KLUK MJ: Lysophospholipids - receptor revelations. Science (2001) 294:1875–1878.
   PubMed Web of Science ®Google Scholar
• •Review of lysophospholipid receptors.
   Google Scholar
• NOGUCHI K, ISHII S, SHIMIZU T: Identification of p2y9/GPR23 as a novel G-protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. I Biol. Chem. (2003) 30:30.
   Google Scholar
• ••Identification of a new LPA receptor,LPA4.
   Google Scholar
• CHUN J, GOETZL EJ, HLA T et al: International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev (2002) 54:265–269.
   Google Scholar
• MCINTYRE TM, PONTSLER AV, SILVA AR et al: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR-y agonist. Proc. Natl. Acad Sci. USA (2003) 100:131–1366.
   PubMed Web of Science ®Google Scholar
• •Discovery of PPAR-y as a novel intracellular receptor for LPA.
   Google Scholar
• SCHMIDT A, WOLDE M, THIELE C et al.: Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature (1999) 401:133–141.
   PubMed Web of Science ®Google Scholar
• FISHMAN DA, LIU Y, ELLERBROEK SM, STACK MS: Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. (2001) 61:3194–3199.
   PubMed Web of Science ®Google Scholar
• •The involvement of LPA in ovarian cancer metastasis.
   Google Scholar
• SAWADA K, MORISHIGE K, TAHARA M et al.: Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Cynecol. Oncol. (2002) 87:252–259.
   PubMed Web of Science ®Google Scholar
• •The involvement of LPA in ovarian cancer metastasis.
   Google Scholar
• SAWADA K, MORISHIGE K, TAHARA M et al.: Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res. (2002) 62:6015–6020.
   PubMed Web of Science ®Google Scholar
• •LPA-induced cancer invasion provides the basis for new therapies.
   Google Scholar
• IMAMURA F, HORAI T, MUKAI M, SHINKAI K, SAWADA M, AKEDO H: Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem. Biophys. Res. Commun. (1993) 193:497–503.
   PubMed Web of Science ®Google Scholar
• XU Y, GAUDETTE DC, BOYNTON JD et al.: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. (1995) 1:1223–1232.
   PubMed Web of Science ®Google Scholar
• ••Discovery of LPA in OCAE
   Google Scholar
• MILLS GB, MAY C, MCGILL M, ROIFMAN CM, MELLORS A: A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. (1988) 48: 1066–1071.
   PubMed Web of Science ®Google Scholar
• HU YL, TEE MK, GOETZL EJ et at. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. Natl. Cancer Inst. (2001) 93:762–768.
   Google Scholar
• FANG X, YU S, BAST R et al.: Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian caner cells. Biol. Chem. (2003) (manuscsript submitted).
   Google Scholar
• FANG X, SCHUMMER M, MAO M et al.: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta. (2002) 1582:257–264.
   PubMed Web of Science ®Google Scholar
• GOETZL EJ, DOLEZALOVA H, KONG Y et al: Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G-protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. (1999) 59:5370–5375.
   PubMed Web of Science ®Google Scholar
• FURUI T, LAPUSHIN R, MAO M et al.:Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer. Res. (1999) 5:4308–4318.
   PubMed Web of Science ®Google Scholar
• EDER AM, SASAGAWA T, MAO M, AOKI J, MILLS GB: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer. Res. (2000) 6:2482–2491.
   PubMed Web of Science ®Google Scholar
• SCHULTE KM, BEYER A, KOHRER K, OBERHAUSER S, ROHER HD: Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor Edg4 in differentiated thyroid cancer. Int. J. Cancer(2001) 92:249–256.
   PubMed Web of Science ®Google Scholar
• SHIDA D, KITAYAMA J, YAMAGUCHI H et al: Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPAl. Cancer Res. (2003) 63:1706–1711.
   PubMed Web of Science ®Google Scholar
• MURATA J, LEE HY, CLAIR T et al.: cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. (1994) 269:30479–3084.
   PubMed Web of Science ®Google Scholar
• NAM SW, CLAIR T, KIM YS et al.: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. (2001) 61:6938–6944.
   PubMed Web of Science ®Google Scholar
• KOH E, CLAIR T, WOODHOUSE EC, SCHIFFMANN E, LIOTTA L, STRACKE M: Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer Res. (2003) 63:2042–2045.
   PubMed Web of Science ®Google Scholar
• CLAIR T, AOKI J, NAM SW et al: Autotaxin hydrolyzes phospholipids to produce a migration stimulator, lysophosphatidic acid, or a migration inhibitor, sphingosine-l-phosphate. Cancer Res. (2003). In Press.
   Google Scholar
• XIE Y, GIBBS TC, MUKHIN YV, MEIER KE: Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. I Biol. Chem. (2002) 277:32516–32526.
   Web of Science ®Google Scholar
• •Describes an autocrine LPA loop in the stimulation of prostate cancer cells.
   Google Scholar
• MILLS GB, EDER A, FANG X et al: Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat. Res. (2002) 107:259–83.
   PubMedGoogle Scholar
• •Review of the critical roles of LPA towards ovarian cancer.
   Google Scholar
• MILLS GB, BAST RC Jr, SRI VASTAVA S:Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. Natl. Cancer. Inst. (2001) 93:1437–1439.
   Google Scholar
• TOKUMURA A, HARADA K, FUKUZAWA K, TSUKATANI H: Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta. (1986) 875:31–38.
   PubMedGoogle Scholar
• TOKUMURA A: Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim. Biophys. Acta. (2002) 1582:18–25.
   PubMed Web of Science ®Google Scholar
• TOKUMURA A, KANAYA Y, KITAHARA M, MIYAKE M, YOSHIOKA Y, FUKUZAWA K: Increased formation of lysophosphatidic acids by lysophospholipase D in serum of hypercholesterolemic rabbits. Lipid Res. (2002) 43:307–15.
   PubMed Web of Science ®Google Scholar
• TOKUMURA A, MAJIMA E, KARIYA Y et al: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. I Biol. Chem. (2002) 277:39436–39442.
   Web of Science ®Google Scholar
• •Identification of human plasma lysoPLD as autotaxin.
   Google Scholar
• TOKUMURA A, TOMINAGA K, YASUDA K, KANZAKI H, KOGURE K, FUKUZAWA K: Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors. Cancer (2002) 94:141–51.
   PubMed Web of Science ®Google Scholar
• UMEZU-GOTO M, KISHI Y, TAIRA A et al: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. Cell Biol. (2002) 158:227–233.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the involvement of LPA and lysoPLD in cancer growth and motility.
   Google Scholar
• XIE Y, GIBBS TC, MEIER KE: Lysophosphatidic acid as an autocrine and paracrine mediator. Biochim. Biophys. Acta. (2002) 1582:270–281.
   PubMed Web of Science ®Google Scholar
• BRINDLEY DN,WAGGONER DW: Mammalian lipid phosphate phosphohydrolases. Biol. Chem. (1998) 273:24281–24284.
   Web of Science ®Google Scholar
• TANYI JL, MORRIS AJ, WOLF JK et al.:The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res. (2003) 63:1073–1082.
   PubMed Web of Science ®Google Scholar
• SMYTH SS, SCIORRA VA, SIGAL YJ et al: Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: Studies using chemical inhibitors of lipid phosphate phosphatase activity. J. Biol. Chem. (2003) 8:8.
   Google Scholar
• LEUNG DW: The structure and functions ofhuman lysophosphatidic acid acykransferases. Front Biwa. (2001) 6:D944–953.
   Web of Science ®Google Scholar
• XU Y, SHEN Z, WIPER DW, WU M et at Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAM (1998) 280:719–723.
   PubMed Web of Science ®Google Scholar
• BAKER DL, MORRISON P, MILLER B et al: Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA (2002) 287:3081–3082.
   PubMed Web of Science ®Google Scholar
• MO OL ENAAR WH: Lysophospholipids in the limelight: autotaxin takes center stage. Cell Biol. (2002) 158:197–199.
   PubMed Web of Science ®Google Scholar
• MILLS GB, MOOLENAAR WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 3:582–591.
   PubMed Web of Science ®Google Scholar
• NAM SW, CLAIR T, CAMPO CK, LEE HY, LIOTTA LA, STRACKE ML: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene (2000) 19:241–247.
   PubMed Web of Science ®Google Scholar
• •Describes the role of autotaxin in the metastatic cascade.
   Google Scholar
• YANG SY, LEE J, PARK CG et al.: Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis (2002) 19: 603–608.
   PubMed Web of Science ®Google Scholar
• ERICKSON JR, HASEGAWA Y, FANG X et al.: Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management. Prostaglandins Other Lipid Mediat. (2001) 64:63–81.
   PubMed Web of Science ®Google Scholar
• NATARAJAN V, SCRIBNER WM, HART CM, PARTHASARATHY S: Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. I LipidRes. (1995) 36:2005–2016.
   PubMed Web of Science ®Google Scholar
• STURM A, SUDERMANN T, SCHULTE KM, GOEBELL H, DIGNASS AU: Modulation of intestinal epithelial wound healing M vitro and in vivo by lysophosphatidic acid. Gastroenterology (1999) 117:368–377.
   PubMed Web of Science ®Google Scholar
• LEE H, GOETZL EJ, AN S: Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am. I Physiol. Cell Physiol. (2000) 278:C612–C618.
   Web of Science ®Google Scholar
• WATSKY MA, GRIFFITH M, WANG DA, TIGYI GJ: Phospholipid growth factors and corneal wound healing. Ann. N 11.- Acad. Sci.(2000) 905:142–158.
   PubMed Web of Science ®Google Scholar
• BALAZS L, OKOLICANY J, FERREBEE M, TOLLEY B, TIGYI G: Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am. I Physiol Rego]. Integi: Comp. Physiol. (2001) 280:R466–472.
   PubMed Web of Science ®Google Scholar
• OKUSA MD, YE H, HUANG L, SIGISMUND L, MACDONALD T, LYNCH KR: Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. Physiol Renal. Physiol (2003) 285(3):F565–F674.
   Web of Science ®Google Scholar
• ••Use of receptor-selective LPA agonists andantagonists in vivo to define the function of particular LPA receptors in ischaemia reperfusion.
   Google Scholar
• VAN NIEUW AMERONGEN GP, VERMEER MA, VAN HINSBERGH VW: Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler. Thromb. Vase. Biol. (2000) 20:E127–E133.
   Web of Science ®Google Scholar
• TOKUMURA A, IIMORI M, NISHIOKA Y, KITAHARA M, SAKASHITA M, TANAKA S: Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am. .1 Physiol (1994) 267:C204–C210.
   Google Scholar
• TOKUMURA A, YOTSUMOTO T, MASUDA Y, TANAKA S: Vasopressor effect of lysophosphatidic acid on spontaneously hypertensive rats and Wistar Kyoto rats. Res. Commun. Mol Pathol Pharmacol (1995) 90:96–102.
   PubMed Web of Science ®Google Scholar
• CERUTIS DR, NOGAMI M, ANDERSON JL et al.: Lysophosphatidic acid and EGF stimulate mitogenesis in human airway smooth muscle cells. Am. J. Physiol (1997) 273110–L15.
   Google Scholar
• TOEWS ML, USTINOVA EE, SCHULTZ HD: Lysophosphatidic acid enhances contractility of isolated airway smooth muscle. Appl. Physiol (1997) 83:1216–1222.
   PubMed Web of Science ®Google Scholar
• RIZZA C, LEITINGER N, YUE J et al: Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab. Invest. (1999) 79:1227–1235.
   PubMed Web of Science ®Google Scholar
• SCALIA R, PRUEFER D, LEFER AM: A novel lysophosphatidic acid analog, LXR-1035, inhibits leukocyte-endothelium interaction via inhibition of cell adhesion molecules. Leukoc. Biol. (2000) 67:26–33.
   PubMed Web of Science ®Google Scholar
• HAYASHI K, TAKAHASHI M, NISHIDA W et al.: Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. (2001) 89:251–258.
   PubMedGoogle Scholar
• GOETZL EJ, KONG Y, VOICE JK: Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. Immunol (2000) 164:4996–1499.
   Web of Science ®Google Scholar
• ZHENG Y, VOICE JK, KONG Y, GOETZL EJ: Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. Faseb J(2000) 14:2387–2389.
   PubMed Web of Science ®Google Scholar
• ZHENG Y, KONG Y, GOETZL EJ: Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. Immunol (2001) 166:2317–2322.
   Web of Science ®Google Scholar
• HUANG MC, GRAELERM, SHANKAR G, SPENCER J, GOETZL EJ: Lysophospholipid mediators of immunity and neoplasia. Biochim. Biophys Acta. (2002) 1582:161–167.
   PubMed Web of Science ®Google Scholar
• GRALER MH, GOETZL EJ: Lysophospholipids and their G-protein-coupled receptors in inflammation and immunity. Biochim. Biophys. Acta. (2002) 1582:168–174.
   PubMed Web of Science ®Google Scholar
• LEE H, LIAO JJ, GRAELER M, HUANG MC, GOETZL EJ: Lysophospholipid regulation of mononuclear phagocytes. Biochim. Biophys. Acta. (2002) 1582:175–177.
   PubMed Web of Science ®Google Scholar
• GOETZL EJ, GRAELER M, HUANG MC, SHANKAR G: Lysophospholipid growth factors and their G-protein-coupled receptors in immunity, coronary artery disease, and cancer. Scientific Worldlournal (2002) 2:324–338.
   PubMedGoogle Scholar
• GOBEIL F Jr, BERNIER SG, VAZQUEZ-TELLO A et al: Modulation of pro-imflammatory gene expression by nuclear lysophosphatidic acid receptor Type-1. f Biol. Chem. (2003) 7:7.
   Google Scholar
• FUKUSHIMA N, CHUN J: The LPA receptors. Prostaglandins (2001) 64:21–32.
   PubMed Web of Science ®Google Scholar
• FUKUSHIMA N, ISHII I, CONTOS JJA, WEINER JA, CHUN J: Lysophospholipid receptors. Anna. Rev. Pharmacol Toxicol (2001) 41:507–534.
   PubMed Web of Science ®Google Scholar
• VAN CORVEN EJ, GROENINK A, JALINK K, EICHHOLTZ T, MOOLENAAR WH: Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell (1989) 59:45–54.
   PubMed Web of Science ®Google Scholar
• ••Observation that LPA has growth factor- like activities, and signals in a strictly G-protein-dependent manner.
   Google Scholar
• JALINK K, EICHHOLTZ T, POSTMA FR, VAN CORVEN EJ, MOOLENAAR WH: Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Difik (1993) 4:247–255.
   PubMedGoogle Scholar
• ••First demonstration that LPA inducesneurite retraction in neuroblastoma cells.
   Google Scholar
• HORDIJK PL, VERLAAN I, VAN CORVEN EJ, MOOLENAAR WH: Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p2lras pathway. Biol Chem. (1994) 269:645–651.
   Google Scholar
• KUMAGAI N, MORII N, FUJISAWA K, NEMOTO Y, NARUMIYA S: ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. Bid Chem. (1993) 268: 24535–24538.
   Web of Science ®Google Scholar
• VAN CORVEN EJ, HORDIJK PL, MEDEMA RH, BOS JL, MOOLENAAR WH: Pertussis toxin-sensitive activation of p2lras by G-protein-coupled receptor agonists in fibroblasts. Proc. Natl. Acad. Sd. USA (1993) 90:1257–61.
   PubMed Web of Science ®Google Scholar
• ••First paper to state that G-protein-coupledreceptor ligands, including LPA, can activate Ras via pertussis toxin-sensitive Gi and a putative protein tyrosine kinase.
   Google Scholar
• VAN DIJK MC, POSTMA F, HILKMANN H, JALINK K, VA NBLITTERSWIJK WJ, MOOLENAAR WH: Exogenous phospholipase D generates lysophosphatidic acid and activates Ras, Rho and Ca2+ signaling pathways. Curr B1'01(1998) 8:386–392.
   PubMed Web of Science ®Google Scholar
• ••First demonstration that a secretedphospholipase D (of bacterial origin) can generate LPA and activate LPA signaling pathways in mammalian cells.
   Google Scholar
• KRANENBURG O, POLAND M, VAN HORCK FP, DRECHSEL D, HALL A, MOOLENAAR WH: Activation of RhoA by lysophosphatidic acid and Gc,12/13 subunits in neuronal cells: induction of neurite retraction. Mo/Bio/(1999) 10: 1851-1857.
   Google Scholar
• FANG X, YU S, LAPUSHIN R et al: Lysophosphatidic acid prevents apoptosis in fibroblasts via G,- protein-mediated activation of mitogen-activated protein kinase. Biochem. (2000) 352:135–143.
   Google Scholar
• KRANENBURG O,MOOLENAAR WH: Ras-MAP kinase signaling by lysophosphatidic acid and other G-protein-coupled receptor agonists. Oncogene (2001) 20:1540–1546.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN FN, OLIVO C, GRIVELL S, GIEPMANS BN, COLLARD JG, MOOLENAAR WH: Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiaml. Bid Chem. (2003) 278:400–406.
   Web of Science ®Google Scholar
• •Demonstrates that LPA1 receptors signal Rac activation and cell migration via the invasion-inducing GDP/GTP exchange factor Tiarnl.
   Google Scholar
• GOETZL EJ, AN S: Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB.I. (1998) 12:1589–1598.
   PubMed Web of Science ®Google Scholar
• CHUN J: Lysophospholipid receptors: implications for neural signaling. Crit. Rev. Neurobiol. (1999) 13:151–168.
   PubMedGoogle Scholar
• MOOLENAAR WH, KRANENBURG O, POSTMA FR, ZONDAG GCM: Lysophosphatidic acid: G-protein-signalling and cellular responses. Curr. Opin. Cell Biol. (1997) 9:168–173.
   PubMed Web of Science ®Google Scholar
• GUO Z, LILIOM K, FISCHER DJ et al.: Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes. Proc. Natl. Acad. Sci. USA (1996) 93:14367–14372.
   PubMed Web of Science ®Google Scholar
• ERICKSON JR, ESPINAL G, MILLS GB: Analysis of the Edg2 receptor based on the structure activity relationship of LPA. Ann. NY Acad. Sci. (2000) 95:279–281.
   Google Scholar
• ••SAR analysis of LPA towards Edg2provides basis for further development of LPA receptor modulators.
   Google Scholar
• BANDOH K, AOKI J, HOSONO H et al.: Molecular cloning and characterization of a novel human G-protein-coupled receptor, Edg7, for lysophosphatidic acid. Biol. Chem. (1999) 274:27776–27785.
   Web of Science ®Google Scholar
• BANDOH K, AOKI J, TAIRA A, TSUJIMOTO M, ARAI H, INOUE K: Lysophosphatidic acid (LPA) receptors of the Edg family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. (2000) 478:159–165.
   Google Scholar
• ••SAR analysis of LPA receptors providesbasis for further development of subtype-specific LPA receptor modulators.
   Google Scholar
• MOOLENAARWH: Lysophosphatidic acid, a multifunctional phospholipid messenger. Biol Chem. (1995) 270:12949–12952.
   Google Scholar
• MOOLENAAR WH: Bioactive lysophospholipids and their G-protein-coupled receptors. Exp. Cell Res. (1999) 253:230–238.
   PubMed Web of Science ®Google Scholar
• XU Y, XIAO YJ, BAUDHUIN LM, SCHWARTZ BM: The role and clinical applications of bioactive lysolipids in ovarian cancer. J. Soc. Cynecol Investig. (2001) 8:1–13.
   PubMedGoogle Scholar
• VIRAG T, ELROD DB, LILIOM K et al.: Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2003) 63:1032–1042.
   PubMed Web of Science ®Google Scholar
• ••Molecular modeling directed LPA receptorligand design.
   Google Scholar
• WANG DA, LORINCZ Z, BAUTISTA DL, LILIOM K, TIGYI G, PARRILL AL: A single amino acid determines lysophospholipid specificity of the S1P1 (Edgl) and LPA1 (Edg2) phospholipid growth factor receptors. 'Bib/. Chem. (2001) 276:49213–49220.
   PubMed Web of Science ®Google Scholar
• ••Critical information for design of subtype-selective LPA receptor ligands.
   Google Scholar
• SARDAR VM, BAUTISTA DL, FISCHER DJ et al.: Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim. Biophys. Acta. (2002) 1582:309–317.
   PubMed Web of Science ®Google Scholar
• ••Review of molecular information forrational design of subtype-selective LPA receptor ligands.
   Google Scholar
• HASEGAWA Y, ERICKSON JR, GODDARD GJ et al.: Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. Biol. Chem. (2003) 278:11962–11969.
   Web of Science ®Google Scholar
• •OMPT as an LPA3-specific ligand.
   Google Scholar
• FISCHER DJ, NUSSER N, VIRAG T et al.: Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2001) 60:776–784.
   PubMed Web of Science ®Google Scholar
• •Subtype-specific LPA receptor antagonists, DGPP.
   Google Scholar
• SUGIURA T, TOKUMURA A, GREGORY L, NOUCHI T, WEINTRAUB Si HANAHAN DJ: Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor. Arch. Biochem. Biophys. (1994) 311:358–368.
   PubMed Web of Science ®Google Scholar
• LYNCH KR,MACDONALD TL: Structure-activity relationships of lysophosphatidic acid analogs. Biochim. Biophys. Acta. (2002) 1582: 289–294.
   PubMed Web of Science ®Google Scholar
• ••Review of SAR for rational design ofsubtype-selective LPA receptor ligands.
   Google Scholar
• GUEGUEN G, GAIGE B, GREVY JM et al.: Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation. Biochemistry (1999) 38:8440–8450.
   PubMed Web of Science ®Google Scholar
• •SAR study of LPA towards its biological function.
   Google Scholar
• LILIOM K, BITTMAN R, SWORDS B, TIGYI G: N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. Molec. Pharmacol. (1996) 50:616–623.
   PubMed Web of Science ®Google Scholar
• •Illustrates LPA analogues based on the amino acid backbones.
   Google Scholar
• HOOKS SB, SANTOS WL, IM DS, HEISE CE, MACDONALD TL, LYNCH KR Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J. Bib/. Chem. (2001) 276:4611–4621.
   PubMed Web of Science ®Google Scholar
• SHEN Z, WU M, ELSON Pet a/.: Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Cynecol. Oncol. (2001) 83:25–30.
   Google Scholar
• XIAO YJ, SCHWARTZ B, WASHINGTON M et al: Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem (2001) 290:302–313.
   PubMed Web of Science ®Google Scholar
• XU Y, PRESTWICH GD: Concise synthesis of acyl migration-blocked 1, 1-difluorinated analogues of lysophosphatidic acid. I. Org. Chem. (2002) 67:7158–7161.
   PubMed Web of Science ®Google Scholar
• XU Y, PRESTWICH GD: Synthesis of chiral (a,a-difluoroalkAphosphonate analogues of (lyso)phosphatidic acid via hydrolytic kinetic resolution. Org Lett (2002) 4:4021–4024.
   PubMed Web of Science ®Google Scholar
• •Synthesis of metabolically stable PA and LPA analogues including the LPP inhibitor.
   Google Scholar
• XU Y, QIAN L, PRESTWICH GD: Synthesis of monofluorinated analogues of lysophosphatidic acid. I. Org. Chem. (2003) 68:5320–5330.
   PubMed Web of Science ®Google Scholar
• •Describes synthesis of biologically active metabolically stable LPA analogues.
   Google Scholar
• XU Y, QIAN L, PRESTWICH GD: Synthesis of a-fluorinated phosphonates from a-fluorovinylphosphonates: a new route to analogues of lysophosphatidic acid. Org. Lett. (2003) 5:2267–2270.
   PubMed Web of Science ®Google Scholar
• IMAI A, FURUI T, TAMAYA T, MILLS GB: A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J. Clin. Endocrinol Metal, (2000) 85:3370–3375.
   PubMed Web of Science ®Google Scholar
• FOURCADE O, SIMON ME VIODE C et al.: Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell (1995) 80:919–927.
   Google Scholar
• SONODA H, AOKI J, HIRAMATSU T et al: A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid.' Biol. Chem. (2002) 277:34254–34263.
   Web of Science ®Google Scholar
• SANO I BAKER D, VIRAG T et al.: Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. Biol Chem. (2002) 277:21197–21206.
   Google Scholar
• AOKI J, TAIRA A, TAKANEZAWA Yet al.: Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. (2002) 277:48737–48744.
   Google Scholar
• HINOKIO K, YAMANO S, NAKAGAWA K etal.: Lysophosphatidic acid stimulates nuclear and cytoplasmic maturation of golden hamster immature oocytes in vitro via cumulus cells. Life Sci. (2002) 70:759–767.
   Google Scholar
• XIAO Y, CHEN Y, KENNEDY AW, BELINSON J, XU Y: Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. NY Acad Sci. (2000) 905:242–259.
   PubMed Web of Science ®Google Scholar
• FERRY G, TELLIER E, TRY A et at: Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. j Biol. Chem. (2003) 278:18162–18169.
   Google Scholar
• SCIORRA VA, MORRIS AJ: Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim. Biophys. Acta. (2002) 1582:45–51.
   PubMed Web of Science ®Google Scholar
• BRAUER AU, SAVASKAN NE, KUHN H, PREHN S, NINNEMANN O, NITSCH R: A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat. Neurosci. (2003) 6:572–578.
   PubMed Web of Science ®Google Scholar
• SEIDEN M: Highlights in ovarian cancer. Oncologist (2000) 5:267–273.
   PubMedGoogle Scholar
• TRIMBLE E: Innovative therapies for advanced ovarian cancer. Semin. Oncol. (2000) 27:24–30.
   PubMed Web of Science ®Google Scholar
• GOGARTEN W, EMALA CW, LINDEMAN KS,HIRSHMAN CA: Oxytocin and lysophosphatidic acid induce stress fiber formation in human myometrial cells via a pathway involving Rho-kinase. Biol. Reprod. (2001) 65:401–406.
   PubMed Web of Science ®Google Scholar
• CONTOS JJ, FUKUSHIMA N, WEINER JA, KAUSHAL D,CHUN J: Requirement for the LPA1 lysophosphatidic acid receptor gene in normal suckling behavior. Pr. Natl. Acad. Sci. USA (2000) 97:13384–13389.
   PubMed Web of Science ®Google Scholar
• •Demonstration that LPA1 knockout mice have reduced viability due to defects in suckling behaviour.
   Google Scholar
• CONTOS JJ, ISHII I, FUKUSHIMA Net al: Characterization of LPA(2) (Edg4) and LPA(1)/LPA(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to LPA(2). Mol Cell Biol. (2002) 22:6921–6929.
   PubMed Web of Science ®Google Scholar
• •Demonstration that compound LPA1/ LPA2 knockout mice have a phenotype that is not significantly different from LPA1 knockout mice.
   Google Scholar
• PUSTILNIK TB, ESTRELLA V, WIENER JR et al: Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Cl/n. Cancer. Res. (1999) 5:3704–3710.
   PubMed Web of Science ®Google Scholar
• PARRILL AL, WANG D, BAUTISTA DL et al.: Identification of Edgl receptor residues that recognize sphingosine 1-phosphate. Biol. Chem. (2000) 275:39379–39384.
   Web of Science ®Google Scholar
• PARRILL AL, BAKER DL, WANG DA et al: Structural features of Edg 1 receptor-ligand complexes revealed by computational modeling and mutagenesis. Ann. NY Acad. Sci.(2000) 905:330–339.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, LYNCH KR: FTY-720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curt: Opin. Immunol. (2002) 14:569–575.
   Google Scholar
• MAKI T, GOTTSCHALK R, MONACO AP: Prevention of autoimmune diabetes by FTY-720 in nonobese diabetic mice. Transplantation (2002) 74: 1684-1686.
   Google Scholar
• FUJINO M, FUNESHIMA N, KITAZAWA Y et al: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY-720 treatment. Pharmacol Exp. Ther: (2003) 305:70–77.
   Google Scholar
• YANG Z, CHEN M, FIALKOW LB et al.: The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice small star, filled. Clin. Immunol. (2003) 107:30–35.
   PubMed Web of Science ®Google Scholar
• AZUMA H, HORIE S, MUTO S et al.: Selective cancer cell apoptosis induced by FTY-720; evidence for a Bcl-dependent pathway and impairment in ERK activity. AntiCancer Res. (2003) 23:3183–3193.
   PubMed Web of Science ®Google Scholar
• AZUMA H, TAKAHARA S, ICHIMARU N et al: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY-720, in mouse breast cancer models. Cancer Re.s (2002) 62:1410–1419.
   PubMed Web of Science ®Google Scholar